Einstein Responds to the Urgent Need for Effective Ebola Treatments


Our back-to-back papers in Cell Host & Microbe describe the development of an antibody cocktail that can protect animals against all three ebolaviruses associated with human disease outbreaks. This cocktail, MBP134, has set new benchmarks in both antiviral breadth and therapeutic efficacy.

Our industrial partner, Mapp Biopharmaceutical, is developing MBP134 for human use in collaboration with the U.S. Biomedical Advanced Research and Development Authority (BARDA). in rodent and large-animal models of lethal ebolavirus disease.

This work represents the efforts of an amazing international consortium of scientists from academia, government, and industry, including Einstein, Mapp Biopharmaceutical, Adimab LLC, Public Health Agency of Canada, United States Army Medical Institute of Infectious Diseases (USAMRIID), University of Texas-Medical Branch, and Massachusetts General Hospital. Stay tuned for more exciting work from our posse!

Go here for my Q&A about our findings and their importance for developing a broadly protective therapy against ebolavirus disease.

Read an independent take on our work here.

Study Identifies How Hantaviruses Infect Lung Cells

Check out highlights of our work to discover a new receptor for hantaviruses that cause severe pulmonary syndrome (HPS) in the New World on the Einstein and NIH websites. We believe that this receptor could provide a target for the development of therapeutics to protect against HPS.

This study is a great example of the power of dispersed collaborative teams to do interdisciplinary science. The Chandran Lab’s Rohit Jangra and other lab members drove these efforts, but other labs from three continents also played key roles. Thank you to John Dye, Zhongde Wang, Thijn Brummelkamp, Jason Moffat, Félix Rey, Nicole Tischler, Dev Sidhu, and Jon Lai and all of their participating group members for making this happen.

Perseverance Pays Off in Fight Against Deadly Lassa Virus


Read about the quest to glimpse the molecular details of Lassa virus glycoprotein in complex with human neutralizing antibodies by our collaborators at the Saphire Lab.

The Chandran Lab’s Lara Kleinfelter helped elucidate the mode of action of the human antibodies by demonstrating inhibition of viral fusion in cells through stabilization of the pre-fusion conformation of the Lassa virus glycoprotein.  

Antibodies from Ebola survivor could lead to treatments and vaccines


Check out a highlight of our work on pan-ebolavirus neutralizing antibodies in the NIH Research Matters newsletter. 

“Since it’s impossible to predict which of these agents will cause the next epidemic, it would be ideal to develop a single therapy that could treat or prevent infection caused by any known ebolavirus,” - Zach Bornholdt, PhD

Antibodies from Ebola survivor protect mice and ferrets against related viruses


Read about how our NIAID-funded study could lead to broad, versatile treatments for many different Ebolaviruses.

Researchers funded in part by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have studied the blood of an Ebola survivor, searching for human antibodies that might effectively treat not only people infected with Ebola virus, but those infected with related viruses as well. Now the researchers have identified two such antibodies that hold promise as Ebola treatments.

How to turn competitors into collaborators

Commentary in Nature highlights the power of cross-institutional collaborations and lessons learned by the team as they make headway on finding better treatments for Ebola virus infection. The Chandran Lab is an integral part of the Viral Hemorrhagic Fever Immunotherapeutic Consortium, contributing key functional assays that characterize neutralization activity of monoclonal antibodies and help predict their therapeutic potential. 

New 'Trojan Horse' Antibody Strategy Shows Promise Against All Ebola Viruses

In our new paper in Science, we describe a new therapeutic strategy to target a hidden Achilles’ heel shared by all known types of Ebola virus. This strategy relies on our development of unique bispecific antibodies that like the mythical "Trojan horse," trick Ebola into carrying the means of its own destruction into host cells. See the press release here

Fatal Attachment: Watch the Ebola virus fusion machine in action inside a human cell

Like a Trojan horse, Ebola virus sneaks into a human cell by hiding out inside lysosomes. In order to escape from the lysosome, the virus must then fuse its membrane with the membrane of the lysosome. Live imaging captures this moment of fusion in brilliant color. Images by Chandran Lab postdoctoral fellow, Dr. Jennifer Spence.

Understanding the Ebola virus

The Ebola epidemic in west Africa has highlighted the threat of emerging infectious diseases to public health. In this Nature.com webcast (registration required), Kartik outlines the importance of basic molecular research to understand how Ebola enters human cells, and why such research has been key to developing drugs and vaccines. Dr. Simon Hay (University of Oxford) also explains how mapping and modeling can help identify where are the places where Ebola and other emerging diseases risk jumping from animals to people. Watch the video (Kartik's talk only, 21 minutes).